KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Shares Outstanding (Diluted Average): 2009-2025

Historic Shares Outstanding (Diluted Average) for Ionis Pharmaceuticals (IONS) over the last 11 years, with Sep 2025 value amounting to $159.8 million.

  • Ionis Pharmaceuticals' Shares Outstanding (Diluted Average) rose 7.52% to $159.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $159.8 million, marking a year-over-year increase of 7.52%. This contributed to the annual value of $149.5 million for FY2024, which is 4.42% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $159.8 million for Q3 2025, which was down 12.38% from $182.3 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $182.3 million in Q2 2025 and a low of $140.8 million during Q1 2021.
  • For the 3-year period, Ionis Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $151.2 million, with its median value being $146.0 million (2024).
  • Data for Ionis Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY increased of 24.92% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $141.0 million in 2021, then increased by 0.59% to $141.8 million in 2022, then increased by 0.95% to $143.2 million in 2023, then rose by 4.42% to $149.5 million in 2024, then rose by 7.52% to $159.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $159.8 million for Q3 2025, versus $182.3 million for Q2 2025 and $158.7 million for Q1 2025.